Trends & Analysis

#Biotechnology #Clinical trials #CRISPR #Market reporting #Therapeutics

Report predicts trends and forecasts for CRISPR 

The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.  The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected to… Read More

#News #Trends & Analysis

#Business #Pharmaceuticals

South Korea’s drug pricing could boost pharma innovation, says data 

South Korea is supporting innovative pharmaceutical companies by revising the health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData.  According to GlobalData, the pharmaceutical market in South Korea is estimated to grow at a compound annual growth… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#Biotechnology #Infographic

Infographic: Biotech hot spots in a fragmented European landscape 

McKinsey has mapped out 1,382 biotechs based in Europe and some interesting themes emerged, showing how European biotechs have established a position of strength from which to enter the industry’s next act. Over the past three years, Europe’s biotech industry has made meaningful progress on attracting capital and bringing products to market.  Europe’s complex biotech… Read More

#Market Reports #News #Trends & Analysis

#Biotherapeutics #Gene therapy #Global data

Gene therapies could revolutionise CVDs, data says 

Gene therapies could revolutionise the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The data and analytics company notes that there are currently 87* CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life.  Fiona Chisholm, Pharma Analyst at GlobalData said: “As… Read More

#Market Reports #News #Trends & Analysis

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Valneva begins submission to MHRA for its Covid-19 vaccine 

Valneva has begun a rolling submission for initial approval of its Covid-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in… Read More

#Covid-19 #News #Trends & Analysis

#Precision medicine #Report #Research

The Operationalisation of Precision Medicine report

Public Policy Projects (PPP) has launched a new report called ‘The Operationalisation of Precision Medicine.' The report, which is now available to download, has been created in partnership with AstraZeneca. Precision medicine is a development in medical history that has the potential to ensure better outcomes for patients. The UK… Read More

#Market Reports #News #Trends & Analysis

#Biotechnology #Biotherapeutics #Market reporting

Innovation and opportunity within Europe’s biotech sector

Listen to this article on the DDW Podcast: Lu Rahman introduces a slice of European biotech expertise Thanks to the Covid-19 pandemic, the global biotech sector has been thrown into the spotlight, not just in the drug discovery and development word, but as a sector that the general public has come… Read More

#Editor's Choice #Exclusive Content #Intelligence #Market Reports #News #Opinion #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#Biotherapeutics #Clinical research #Microbiome #Therapeutics

Report reveals the potential of microbiome-targeting therapeutics

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More

#Market Reports #News #Trends & Analysis

#Biopharmaceuticals #Biotechnology #Covid-19 #Health #Life sciences

UK pharma sees R&D spend hold up despite Brexit and Covid-19

A survey of 75 pharmaceutical, life sciences and medtech businesses indicates R&D spending is being maintained and is set to rise in 2021, despite Brexit and the impact of Covid-19. The survey included SMEs in these sectors in the UK and was conducted by accountancy group MHA. This is positive… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis

#Clinical trials #Covid-19 #Data #GlobalData #Immunology / Virology & Vaccines

Covid-19 vaccine and therapeutic trials show different trends

Since Covid-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was seen in the month of April 2020. There has since been a steady decrease in new clinical trial investigations, except for the months of December… Read More

#News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Deep learning #Drug discovery #Pharmaceutical

Opportunities and challenges for AI in drug discovery

By Naheed Kurji, Co-founder and Executive of the Alliance for Artificial Intelligence in Healthcare (AAIH), CEO of Cyclica; and Andreas Windemuth, Ph.D, Chief Science Officer of Cyclica Over the past decade, a new industry has arisen that seeks to apply artificial intelligence (AI), or more aptly machine learning (ML) technologies,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis